Odyssey Health Inc. Overview
Pro stress-test →Odyssey Health, Inc. is a medical company focused on the development and acquisition of medical products and health related technologies. The company is developing CardioMap, a heart monitoring and screening device, and Save-A-Life choking rescue device. As a micro-cap OTC-traded entity, Odyssey operates as a technology and asset acquisition platform targeting life-saving medical solutions.
Strategic Profile
Pro stress-test →Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies, focused on areas with identified technological advantage, superior clinical utility, and substantial market opportunity. The company has also pursued neurological therapies, including a concussion treatment program, though in December 2023 stockholders approved the sale of its neurological drug therapies and technologies to Oragenics, Inc. for $1 million in cash and 8 million shares of convertible preferred stock.
Competitive Landscape
Pro stress-test →Odyssey operates in fragmented medical device and pharmaceutical spaces without direct single-product competitors. The company competes indirectly against established cardiovascular monitoring platforms (e.g., Holter monitors, wearable ECG devices from companies like Apple, Medtronic), emergency response devices, and large pharmaceutical firms developing concussion/neurological treatments. Its acquisition-focused strategy positions it against niche medical device consolidators and smaller biotech platforms.
Industry Context
Odyssey Health Inc. operates in Medical device development and acquisition.
Key facts
Founded: 2014 · Headquarters: Las Vegas, US · Employees: N/A · Revenue: N/A · Market cap: $1.7M